loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Ajanta Pharma Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Ajanta Pharma Ltd. 30 Jul 2026 15:09 PM

Q1FY27 Quarterly Result Announced for Ajanta Pharma Ltd.

Pharmaceuticals company Ajanta Pharma announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from operations stood at Rs 1,626 crore in Q1FY27, representing a growth of 25% YoY compared to Rs 1,303 crore in Q1FY26 and a 14.37% QoQ increase from Rs 1,422 crore in Q4FY26.
  • Total income for Q1FY27 was Rs 1,696.86 crore, up 27.68% YoY from Rs 1,328.98 crore in Q1FY26 and up 14.42% QoQ from Rs 1,483.07 crore in Q4FY26.
  • Adjusted EBITDA (excluding forex loss) reached Rs 454 crore in Q1FY27, growing 21% YoY from Rs 377 crore in Q1FY26 and 21.07% QoQ from Rs 375 crore in Q4FY26. The adjusted EBITDA margin stood at 28% for Q1FY27.
  • Profit before tax (PBT) for Q1FY27 was Rs 446.80 crore, up 35% YoY from Rs 331.13 crore in Q1FY26 and up 28.72% QoQ from Rs 347.11 crore in Q4FY26.
  • Net profit (Profit after tax) reported for Q1FY27 was Rs 334.22 crore, an increase of 31% YoY from Rs 255.34 crore in Q1FY26 and a 25.32% QoQ growth from Rs 266.70 crore in Q4FY26.
  • Return on Capital Employed (ROCE) stood at 37% and Return on Net Worth (RONW) stood at 28% as of Q1FY27.

Standalone Financial Highlights:

  • Revenue from operations for Q1FY27 stood at Rs 1,488.67 crore, showing a 23.18% YoY growth from Rs 1,208.56 crore in Q1FY26 and a 22.98% QoQ increase from Rs 1,210.53 crore in Q4FY26.
  • Total income for Q1FY27 was Rs 1,559.49 crore, up 24.84% YoY from Rs 1,249.19 crore in Q1FY26 and 22.46% QoQ from Rs 1,273.51 crore in Q4FY26.
  • Net profit for Q1FY27 was Rs 315.47 crore, a YoY growth of 23.73% from Rs 254.97 crore in Q1FY26 and a QoQ increase of 59.91% from Rs 197.28 crore in Q4FY26.

Business Highlights:

  • Segment-wise Performance (Consolidated):
    • Branded Generics (Total): Reported revenue of Rs 1,059 crore in Q1FY27, up 13% YoY, contributing 66% of total revenue.
    • India (Branded Generics): Revenue stood at Rs 509 crore in Q1FY27, up 24% YoY, contributing 32% of total revenue. The chronic portfolio accounts for 65% of the India business.
    • Asia (Branded Generics): Revenue was Rs 255 crore in Q1FY27, down 16% YoY due to ongoing war impacts, contributing 16% of total revenue.
    • Africa (Branded Generics): Revenue stood at Rs 295 crore in Q1FY27, up 30% YoY, contributing 18% of total revenue.
    • US Generic: Recorded revenue of Rs 487 crore in Q1FY27, showing a significant growth of 57% YoY and contributing 30% of total revenue.
    • Africa Institution: Revenue reached Rs 70 crore in Q1FY27, up 83% YoY, contributing 4% of total revenue.
  • India Market Position: As per IQVIA MAT June 2026, the company's India branded generic performance exceeded Indian Pharmaceutical Market (IPM) growth by 36%. New launches exceeded IPM growth by 76%.
  • US ANDA Status: As of Q1FY27, the company has 55 active ANDAs (excluding 5 tentative), 17 ANDAs under approval, and 51 products currently on the shelf. During the quarter, the company received 3 approvals and launched 2 products.
  • Interim Dividend: The Board of Directors approved a first interim dividend of Rs 32 per equity share (face value of Rs 2 each) for FY27, amounting to a total payout of Rs 400 crore.
  • R&D Expenditure: R&D expenses for Q1FY27 were Rs 66 crore, representing 4% of total revenue. The company employs over 850 scientists.
  • Working Capital: The company reported an improvement in working capital, with inventory days at 63 in FY26 compared to 72 in FY25.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q4FY26 & FY26 results

Q4FY26 Financial Highlights:

  • Revenue from operations at Rs 1,422 crore against Rs 1,170 crore; up 21%.
  • EBITDA at Rs 333 crore against Rs 297 crore; EBITDA at 23%; up 12%.
  • The mark-to-market forex loss stood at Rs 42 crore Excluding this impact, EBITDA stood at Rs 375 crore, reflecting a 26% growth, with an EBITDA margin of 26%.
  • Profit after tax at Rs 267 crore against Rs 225 crore; PAT at 19%; up 18%.

FY26 Financial Highlights:

  • Revenue from operations at Rs 5,453 crore against Rs 4,648 crore; up 17%.
  • EBITDA at Rs 1,395 crore against Rs 1,260 crore; EBITDA at 26%; up 11%.
  • The mark-to-market forex loss stood at Rs 103 crore Excluding this impact, EBITDA stood at Rs 1,498 crore, reflecting a 18% growth, with an EBITDA margin of 27%.
  • Profit after tax at Rs 1,056 crore against Rs 920 crore; PAT at 19%; up 15%.
  • ROCE stood at a healthy level of 33% and RONW at 25%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q3FY26 results

  • Revenue from operations at Rs 1,375 crore against Rs 1,146 crore; up 20%.
  • EBITDA at Rs 382 crore against Rs 321 crore; up 19%; EBITDA at 28%.
  • Profit after tax at Rs 274 crore against Rs 233 crore; PAT at 20%; up 18%.
  • As per IQVIA MAT December 2025, our India branded generic performance exceeded IPM growth by 28%. The higher growth came from Volumes increase, which exceeded IPM by 47% & New launches, which exceeded IPM by 59%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q2FY26 results

  • Revenue from operations at Rs 1,354 crore against Rs 1,187 crore; up 14%.
  • EBITDA at Rs 328 crore against Rs 311 crore; EBITDA at 24%; up 5%.
  • Profit after tax at Rs 260 crore against Rs 216 crore; PAT at 19%; up 20%.
  • The mark-to-market forex loss stood at Rs 41 crore Excluding this impact, EBITDA stood at Rs 369 crore, reflecting a 9% growth, with an EBITDA margin of 27%. PAT grew by 23%, with a PAT margin of 22%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q1FY26 results

  • Revenue from operations at Rs 1,303 crore. against Rs 1,145 crore; up 14%.
  • EBITDA at Rs 351 crore. against Rs 330 crore, up 6%; EBITDA at 27%.
  • Profit after tax at Rs 255 crore. against Rs 246 crore; up 4%; PAT at 20%.
  • The mark-to-market forex loss stood at Rs 25 crore. Excluding this impact, EBITDA stood at Rs 376 crore, reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%.
  • Cashflow from operations (CFO) was Rs 282 crore, EBITDA to CFO conversion of 80%.
  • Free cashflow (FCF) was Rs 209 crore, FCF to PAT conversion of 82%.
  • ROCE stood at a healthy level of 33% and RONW at 26%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q4FY25 & FY25 results

Q4FY25 FInancial Highlights:

  • Revenue from operations at Rs 1,170 crore against Rs 1,054 crore; up 11%.
  • EBITDA at Rs 297 crore against Rs 278 crore; up 7%; EBITDA at 25%.
  • Profit after tax at Rs 225 crore against Rs 203 crore; up 11%; PAT at 19%.

FY25 FInancial Highlights:

  • Revenue from operations at Rs 4,648 crore against Rs 4,209 crore; up 10%.
  • EBITDA at Rs 1,260 crore against Rs 1,172 crore; up 7%; EBITDA at 27%.
  • Profit after tax at Rs 920 crore against Rs 816 crore; up 13%; PAT at 20%.
  • Cashflow from operations (CFO) was Rs 1,157 crore, EBITDA to CFO conversion of 92%.
  • Free cashflow (FCF) was Rs 694 crore, FCF to PAT conversion of 75%.
  • ROCE stood at a healthy level of 32% and RONW at 25%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q3FY25 results

  • Revenue from operations at Rs 1,146 crore against Rs 1,105 crore; up 4%.
  • EBITDA at Rs 321 crore against Rs 314 crore; up 2%; EBITDA at 28%.
  • Profit after tax at Rs 233 crore against Rs 210 crore; up 11%; PAT at 20%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Revenue from operations at Rs 1,187 crore against Rs 1,028 crore; up 15%.
  • EBITDA at Rs 311 crore against Rs 291 crore; up 7%; EBITDA at 26%.
  • Profit after tax at Rs 216 crore against Rs 195 crore; up 11%; PAT at 18%.

H1FY25 Financial Highlights:

  • Revenue from operations at Rs 2,332 crore against Rs 2,049 crore; up 14%.
  • EBITDA at Rs 642 crore against Rs 572 crore; up 12%; EBITDA at 28%.
  • Profit after tax at Rs 462 crore against Rs 403 crore; up 15%; PAT at 20%.
  • Cashflow from operations (CFO) was Rs 776 crore, EBITDA to CFO conversion of 121%.
  • Free cashflow (FCF) was Rs 322 crore, FCF to PAT conversion of 70%.
  • ROCE stood at a healthy level of 34% and RONW at 26%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q1FY25 results:

  • Revenue from operations at Rs 1,145 crore against Rs 1,021 crore; up 12%.
  • EBITDA at Rs 330 crore against Rs 271 crore; up 22%; EBITDA at 29%.
  • Profit after tax at Rs 246 crore against Rs 208 crore; up 18%; PAT at 21%.
  • Cashflow from operations (CFO) was Rs 466 crore, EBITDA to CFO conversion of 141%.
  • Free cashflow (FCF) was Rs 301 crore, FCF to PAT conversion of 123%.
  • Shareholders pay-out of Rs 351 crore in June 2024 through buyback of shares at a price of Rs 2,770 per equity share, constituting 0.82% of the total paid-up equity share capital.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations at Rs 1,054 crore against Rs 882 crore; up 20%.
  • EBITDA at Rs 278 crore against Rs 149 crore; up 86%; EBITDA at 26%.
  • Profit after tax at Rs 203 crore against Rs 122 crore; up 66%; PAT at 19%.

FY24 Financial Highlights:

  • Revenue from operations at Rs 4,209 crore against Rs 3,743 crore; up 12%.
  • EBITDA at Rs 1,172 crore against Rs 783 crore; up 50%; EBITDA at 28%.
  • Profit after tax at Rs 816 crore against Rs 588 crore; up 39%; PAT at 19%.
  • Cashflow from operations (CFO) was Rs 785 crore, EBITDA to CFO conversion of 67%.
  • Free cashflow (FCF) was Rs 637 crore, FCF to PAT conversion of 78%.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app